SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
This Item 5.07 filing discloses the results of Tyra Biosciences' 2026 Annual Meeting of Stockholders held on May 28, 2026, including voting outcomes for the election of three Class II directors (Habib J. Dable, Susan Moran, and Robert More) and ratification of Ernst & Young LLP as independent auditor. The detailed vote tallies (for, withheld, against, abstentions, broker non-votes) are the core disclosure required under Item 5.07.
View raw filing on EDGAR →Forte Biosciences held its 2026 annual meeting of stockholders on May 29, 2026, with shareholders voting on four matters: election of Class III directors (Kornfeld, Brun, Wagner), ratification of KPMG LLP as independent auditor, advisory approval of named executive officer compensation, and approval of the Amended and Restated 2021 Equity Incentive Plan. All proposals passed with substantial majorities.
View raw filing on EDGAR →Kennametal entered into material definitive credit agreements on May 28, 2026, consisting of a First Amendment increasing revolving credit commitments by $200 million (from $650M to $850M) and a new $500 million unsecured term loan facility, representing a material $700 million increase in aggregate credit capacity and a significant change to the company's capital structure and financial flexibility.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of Taysha Gene Therapies' 2026 annual meeting of stockholders held on June 1, 2026. The filing presents voting results for four proposals: election of two directors (Sean P. Nolan and Laura Sepp-Lorenzino, Ph.D.), ratification of Deloitte & Touche LLP as auditor, advisory approval of named executive officer compensation, and advisory frequency vote on future compensation votes. All proposals passed with substantial majorities, and the Board has determined to solicit advisory votes annually based on stockholder preference.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Evommune's 2026 Annual Meeting of Stockholders held on June 2, 2026. The filing reports voting outcomes for two proposals: (1) election of directors Luis Peña and Eugene Bauer, M.D., and (2) ratification of BDO USA, P.C. as the independent registered public accounting firm. The detailed vote tallies (For, Against, Withheld, Abstain, Broker Non-Votes) are characteristic of Item 5.07 shareholder vote disclosures and are material to investors assessing board composition and auditor selection.
View raw filing on EDGAR →This Item 5.07 disclosure reports the certified results of NETGEAR's 2026 Annual Meeting of Stockholders held on May 28, 2026, including voting outcomes on three proposals: election of six directors, ratification of PricewaterhouseCoopers as independent auditor, and approval of executive compensation. The filing provides detailed vote tallies (for, against, abstain, broker non-votes) for each matter, which is the core content of a shareholder vote results disclosure.
View raw filing on EDGAR →The filing discloses a press release reporting results of operations for the thirteen weeks ended May 2, 2026, furnished as Exhibit 99.1. This is a standard quarterly earnings release disclosure under Item 2.02, which is material to investors as it provides financial performance information for the period.
View raw filing on EDGAR →Jaguar Health issued 64,668 shares of common stock in two privately negotiated exchange transactions with Streeterville Capital in exchange for preferred stock, relying on Section 3(a)(9) exemption. This dilutive equity issuance materially affects shareholder ownership and voting power.
View raw filing on EDGAR →JPMorgan Chase closed a $500 million public offering of Fixed-to-Floating Rate Notes due 2030 on June 2, 2026, as an additional issuance to a prior $2.75 billion offering from April 2026. While this is a material debt issuance that would affect investor assessment of the company's capital structure and leverage, it does not fit neatly into the more specific event categories (it is registered debt, not a dilutive equity issuance under Item 3.02, and not an M&A transaction). This is classified as other_material because it represents a significant financing event disclosed under Item 8.01.
View raw filing on EDGAR →Philippe Busque, Ph.D., Senior Vice President of Global Sales and Services, resigned effective June 5, 2026, to pursue another career opportunity. The disclosure centers on the departure of a named executive officer from a material sales and services leadership role. While the resignation is stated as non-contentious, the loss of an SVP responsible for global sales represents a material change in executive composition that would affect investor assessment of the company's operational continuity.
View raw filing on EDGAR →This Item 5.07 filing discloses the results of Ceribell's 2026 Annual Meeting of Stockholders held on June 2, 2026, including voting outcomes for two proposals: (1) election of Class II directors Josef Parvizi, M.D., Ph.D. and Rebecca Robertson, and (2) ratification of PricewaterhouseCoopers LLP as independent auditor. The disclosure presents vote tallies (For, Against/Withheld, Abstained, Broker Non-Votes) for each proposal, which is the core content of shareholder_vote_results.
View raw filing on EDGAR →Dave Caspers was appointed as President and Chief Executive Officer and Board member of Ardent Health, Inc. effective June 2, 2026, succeeding Martin J. Bonick. The appointment includes an employment agreement and equity grants.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of the Company's 2026 Annual Meeting of Stockholders held on June 1, 2026. The filing presents voting results for two proposals: election of directors David N. Miller and Kevin Shannon, and ratification of Deloitte & Touche LLP as independent auditor. All proposals were approved by the requisite vote. Shareholder vote results are material to investors as they confirm governance and audit oversight decisions.
View raw filing on EDGAR →RPM amended its $300 million accounts receivable securitization facility on May 27, 2026, modifying key financial covenants and terms, including removal of the interest coverage ratio covenant and addition of a leverage ratio covenant, representing a material modification to the Company's financing arrangement and financial flexibility.
View raw filing on EDGAR →TETRA Technologies announced an underwritten public offering of $100 million in common stock with a $15 million over-allotment option, constituting a material dilutive equity issuance that will affect existing shareholders' ownership percentages.
View raw filing on EDGAR →TETRA Technologies disclosed material strategic initiatives including board approval of the final investment decision for the Arkansas Bromine Project with $220 million remaining capex and Phase 2 underway (expected 2028 operation), and a new joint venture with Magrathea Metals for magnesium production.
View raw filing on EDGAR →Primerica amended and restated its $200 million revolving credit facility on June 2, 2026, extending the maturity date to June 2, 2031, modifying the Applicable Margin, and adjusting financial covenants. This refinancing demonstrates the company's ability to secure credit and extends its liquidity runway.
View raw filing on EDGAR →The filing discloses a distribution declaration by a BDC (Business Development Company) for both Class I and Class S common shares, with specific per-share amounts ($0.1191 and $0.1077 net, respectively) payable on June 18, 2026. While distributions are routine for BDCs and do not fit the earnings_release category (which typically involves comprehensive financial results), this material distribution announcement affects shareholder value and would be relevant to investors. The disclosure does not match any more specific event type in the taxonomy, making other_material the most appropriate classification.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from Kyverna's 2026 Annual Meeting of Stockholders held on May 27, 2026. The filing reports the voting outcomes for two proposals: election of two Class II directors (Ian Clark and Christi Shaw) and ratification of BDO USA, P.C. as the independent auditor. The detailed vote tallies (votes for, against, withheld, and broker non-votes) are characteristic of Item 5.07 shareholder vote results disclosures, which are material to investors as they confirm the composition of the board and auditor appointment.
View raw filing on EDGAR →Senior Credit Investments declared a cash distribution of $17.0106 per Unit to unitholders, payable June 18, 2026. While distributions are routine for investment companies and funds, the specific dollar amount and timing would be material to unitholders assessing returns and cash flow. This does not fit neatly into earnings_release (no financial results disclosed) or other specific event types, making other_material the most appropriate classification.
View raw filing on EDGAR →David S. Schulz, Executive Vice President and Chief Financial Officer, retired from the Company effective May 31, 2026, after serving in the role through February 16, 2026. The filing also discloses a post-retirement consulting arrangement.
View raw filing on EDGAR →WESCO held its Annual Meeting of Stockholders on May 28, 2026, at which shareholders voted on three proposals: election of ten directors, advisory approval of named executive officer compensation, and ratification of PricewaterhouseCoopers LLP as independent auditor. All three proposals passed with substantial majorities.
View raw filing on EDGAR →The Company disclosed an updated feasibility study for its Grassy Mountain Gold Project prepared under Regulation S-K subpart 1300, which is a material technical and economic assessment of a major mineral property. While this does not fit neatly into the standard 8-K event categories (not an earnings release, M&A activity, or impairment charge), an updated feasibility study for a 100%-owned project would materially affect investor assessment of the Company's asset value and development prospects, warranting disclosure as a material event.
View raw filing on EDGAR →This is a clear disclosure of shareholder meeting results under Item 5.07, reporting the voting outcomes for four proposals: election of nine directors (all passed with majority support), advisory approval of named executive officer compensation, ratification of PricewaterhouseCoopers LLP as independent auditor, and approval of the 2026 Equity and Incentive Compensation Plan. All proposals passed. This is a material event as it reflects shareholder governance decisions and approval of key corporate matters.
View raw filing on EDGAR →On June 1, 2026, Cue Biopharma appointed Sumita Ray as Chief Legal & Compliance Officer and Corporate Secretary, Michael Meluzio as Vice President and Principal Accounting Officer, and Daniel Camardo and Viola Meehan as directors. The appointments represent material governance and executive leadership changes, including board restructuring from seven to five directors and committee assignments for the new board members.
View raw filing on EDGAR →Todd Heeter was appointed as interim Chief Financial Officer effective May 28, 2026, under a consulting agreement providing $125,000 per month for six months. This appointment follows the departure of Kevin Beth as CFO on May 27, 2026, and Brian Meents as Chief Operating Officer, representing material changes to senior management.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of Dave Inc.'s 2026 Annual Meeting of Stockholders held on June 2, 2026, including voting outcomes on four proposals: election of director Dan Preston, advisory approval of executive compensation, frequency of future advisory votes on compensation, and ratification of Deloitte & Touche LLP as independent auditor. The detailed vote tallies and quorum confirmation (91.05% attendance) are characteristic of shareholder vote result disclosures required under Item 5.07.
View raw filing on EDGAR →Village Farms held its Annual Meeting of Shareholders on June 2, 2026, with voting results on three proposals: election of directors, advisory approval of named executive officer compensation, and re-appointment of KPMG LLP as independent auditor. The detailed vote tallies and percentages are disclosed in the filing.
View raw filing on EDGAR →Vista Credit held its annual meeting of stockholders on May 28, 2026, with final voting results showing the election of director Stephen Riddick (28,073,001 votes for) and ratification of Deloitte & Touche LLP as independent auditor (28,081,520 votes for).
View raw filing on EDGAR →Lawrence Y. Kim was appointed to the additional position of Chief Commercial Officer effective June 1, 2026. While the disclosure also includes compensatory arrangements (salary increase to $850,000, bonus opportunity of 125%, long-term equity awards of $2,000,000 annually, and a $3,000,000 performance retention grant), the principal disclosed action is the appointment to a new executive officer role. The appointment of an executive to a significant new position is material to investors.
View raw filing on EDGAR →Stockholders voted at the Annual Meeting on five proposals: election of three Class III directors (Taylor Schreiber, Helen M. Boudreau, and Clay Siegall), ratification of KPMG LLP as auditor, advisory vote on executive compensation, frequency of future advisory votes (with '1 Year' receiving plurality), and approval of the 2020 Equity Incentive Plan amendment. All proposals passed with the specified voting outcomes.
View raw filing on EDGAR →Avista entered into a non-binding MOU with a developer for a large load electric service project representing 125 MW initially (expandable to 500 MW by 2032) in its Washington service territory. While the MOU is non-binding and subject to regulatory approval and definitive agreements, the scale of the potential load (500 MW) and the multi-year commitment pathway (2029–2032) represent material business development activity that would affect investor assessment of the company's growth prospects and capital requirements. This does not fit neatly into the M&A taxonomy (no acquisition or merger) but is a material commercial commitment warranting disclosure.
View raw filing on EDGAR →Worthington Steel entered into material definitive agreements for $700 million in senior secured notes and a $700 million term loan facility to finance the Klöckner Acquisition, with a special mandatory redemption provision tied to acquisition completion by March 12, 2027.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of ACI Worldwide's 2026 Annual Meeting of Stockholders held on June 2, 2026, including voting outcomes for three proposals: election of nine board directors, ratification of Deloitte & Touche LLP as independent auditor, and advisory approval of named executive compensation. The detailed vote tallies (votes for, against, abstentions, and broker non-votes) for each proposal are the core content, directly matching the shareholder_vote_results event type.
View raw filing on EDGAR →Zaneta Koplewicz resigned from her positions as Co-President, Head of Shareholder Relations, and Board member, effective June 24, 2026. The disclosure centers on her departure from multiple senior executive and board roles, making this a clear executive departure event. The resignation of a Co-President and board director is material to investors' assessment of the company's leadership and governance.
View raw filing on EDGAR →This disclosure centers on an adverse court decision in patent litigation involving CINVANTI, a key product. The District Court held that Heron's asserted claims of U.S. Patent Nos. 12,115,255 and 12,290,520 are invalid (June 1, 2026 decision), which directly threatens the company's ability to block generic competition from Azurity/Slayback. The litigation spans multiple years and involves substantial patent disputes; the adverse ruling is material to investors assessing Heron's product protection and competitive position.
View raw filing on EDGAR →Bret Christensen resigned as Chief Executive Officer of BioTE, effective June 8, 2026. Robert Peterson was appointed as Interim CEO and Marc Beer as Executive Chairman in connection with the departure.
View raw filing on EDGAR →The filing discloses a change in the registrant's independent accountant: BDO USA, P.C. was dismissed on May 29, 2026, and Baker Tilly US, LLP was engaged on June 1, 2026. This is a textbook auditor_change event under Item 4.01. While the disclosure notes no disagreements or adverse opinions from BDO, it does identify a material weakness in internal controls over financial reporting that was remediated by year-end 2025, making the auditor transition material to investors assessing the registrant's financial reporting quality and governance.
View raw filing on EDGAR →Whirlpool announced the pricing of a $2.0 billion private offering of senior secured second lien notes ($1.0 billion due 2031 and $1.0 billion due 2034) sold to qualified institutional buyers under Rule 144A and to non-U.S. persons under Regulation S. While technically debt rather than equity, this unregistered private placement of material securities is a significant capital-raising event that would materially affect investor assessment of the company's financial position and leverage.
View raw filing on EDGAR →Xometry entered into an underwriting agreement on June 1, 2026 for a public offering of 2,647,059 shares of Class A common stock at $85.00 per share, with net proceeds of approximately $215.2 million. This is a registered public offering of equity securities that will dilute existing shareholders. The magnitude (approximately $215 million in gross proceeds) and the explicit underwriting structure make this a material dilutive issuance requiring 8-K disclosure under Item 3.02 (though filed under Item 8.01).
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of Turtle Beach Corporation's 2026 Annual Meeting of Stockholders held on June 2, 2026, including voting outcomes for three proposals: election of six board directors, ratification of Ernst & Young LLP as independent auditor, and an advisory vote on NEO compensation. The detailed vote tallies (for, against, abstain, broker non-votes) for each matter are the core content, matching the shareholder_vote_results taxonomy precisely.
View raw filing on EDGAR →The disclosure centers on the appointment of Bryan Kennedy as a director of Southern First Bancshares, Inc. and Southern First Bank effective June 1, 2026, with assignment to the Risk Committee. While the section also mentions his participation in standard director compensation arrangements, the principal action disclosed is his appointment to the board, making this an exec_appointment event. The material nature is supported by Kennedy's extensive banking background, his role as Lead Independent Director of a NYSE-traded company, and the Boards' explicit statement that his experience will enhance the Company's governance.
View raw filing on EDGAR →The disclosure describes the consummation of a $80 million IPO and concurrent $2.52 million private placement by a SPAC (Burtech Acquisition Corp II), with proceeds deposited in trust. While this is a capital-raising event material to investors, it does not fit cleanly into the standard M&A or dilutive issuance categories—it is the company's own IPO rather than an acquisition or secondary offering. The event is material but best classified as "other_material" given the SPAC structure and trust account mechanics.
View raw filing on EDGAR →The disclosure describes the consummation of Breeze Acquisition Corp. II's IPO on May 14, 2026, generating $140 million in gross proceeds from 14 million units (including over-allotment), plus a concurrent private placement of 470,000 units for $4.7 million. While this is a significant capital-raising event material to investors, it does not fit neatly into the standard 8-K taxonomy—it is neither an earnings release, M&A activity, nor a traditional executive or governance event. The IPO itself is the material event, but the taxonomy lacks a dedicated "IPO" or "capital_raising" category, making "other_material" the most appropriate classification.
View raw filing on EDGAR →This Item 5.07 filing discloses the results of a reconvened Special Meeting of Stockholders held on June 1, 2026, with detailed voting tallies for two proposals: (1) approval of a reverse stock split amendment (4,492,117 FOR vs. 3,361,162 AGAINST) and (2) approval of the 2026 Equity Incentive Plan (4,613,683 FOR vs. 1,527,837 AGAINST). Both proposals were approved by majority vote. The reverse stock split authorization is material as it directly affects share structure and may signal delisting risk mitigation, while the equity plan approval is material to executive compensation and capital allocation.
View raw filing on EDGAR →Bluejay Diagnostics entered into a material definitive agreement with Argonaut Manufacturing Services on May 27, 2026, for comprehensive manufacturing services supporting the Company's Symphony™ platform and IL-6 testing products, including planning, engineering, supply chain management, formulation, filling, quality control, and distribution.
View raw filing on EDGAR →ESAB completed its acquisition of Eddyfi Holding Inc. for $1.45 billion in cash on June 1, 2026. This material acquisition was financed through debt and equity offerings and directly affects the registrant's capital structure and strategic position.
View raw filing on EDGAR →ESAB completed private placements totaling approximately $318 million on June 1, 2026, consisting of 175,000 shares of 6.50% Series A Mandatory Convertible Preferred Stock ($175.0 million) and 1,254,255 shares of common stock ($143.0 million), issued in reliance on Section 4(a)(2) exemptions. The Series A preferred stock features mandatory conversion into common stock (7.1806 to 8.2576 shares per preferred share) approximately three years after issuance, with registration rights agreements requiring the company to maintain resale registration statement effectiveness.
View raw filing on EDGAR →Triller disclosed receipt of a Nasdaq exception to regain compliance with the Bid Price Rule (minimum $1.00 closing bid price for 10 consecutive business days by June 30, 2026). This is a delisting risk disclosure under Item 3.01: the company faces potential delisting if it fails to meet the bid price requirement within the specified cure period. The filing also references prior delisting threats (December 2025 decision, April 2026 trading suspension) that were partially resolved, making the current bid price deficiency a material continuing compliance risk.
View raw filing on EDGAR →The disclosure reports Bitcoin production metrics from a newly acquired subsidiary (CS Digital Ventures, LLC, acquired May 28, 2026) and describes hosting arrangements and operational outlook. While the acquisition itself would typically be classified as ma_activity, this Item 7.01 disclosure focuses on operational metrics and production reporting rather than the acquisition transaction itself. The material nature stems from the recent acquisition and its contribution to the company's operations, but the primary content is operational disclosure under Regulation FD rather than a discrete M&A event announcement.
View raw filing on EDGAR →